CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: September 22, 2014
Result type: Reports
Project Number: SR0398-000
Product Line: Reimbursement Review

Generic Name: Omalizumab

Brand Name: Xolair

Manufacturer: Novartis Pharmaceuticals Canada Inc.

Therapeutic Area: Chronic idiopathic urticaria

Indications: Urticaria, chronic idiopathic

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: May 7, 2015

Recommendation Type: List with clinical criteria and/or conditions